Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GLGelesis Holdings, Inc. logo

Gelesis Holdings, Inc. (GLS)

New York Stock Exchange · Currency in USD
$0.16 ▲ +0.00 (+0.00%)
At close: Apr 10, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.16
Open
$0.15
Day's Range
$0.15 – $0.16
52 Week Range
$0.01 – $5.67
Volume
185,167
Avg. Volume
570,667
Market Cap
$11.63M
Beta (5Y Monthly)
0.99
PE Ratio (TTM)
--
EPS (TTM)
-$0.79
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Gelesis Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
93
CEO
Yishai Zohar

Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.

Earnings

DateEst.Actual
Aug 14, 2023–-$0.10
May 10, 2023–-$0.07
Mar 28, 2023-$0.26-$0.33Miss
Nov 14, 2022-$0.34-$0.20Beat
Sep 16, 2022–-$0.17
May 12, 2022–-$0.09

Analyst view

Rating: Buy
Buy 40% · Hold 20% · Sell 40%

Get free alerts on GLS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.